Matsuzaki, Shinya
Klar, Maximilian
Mikami, Mikio
Shimada, Muneaki
Grubbs, Brendan H.
Fujiwara, Keiichi
Roman, Lynda D.
Matsuo, Koji
Article History
First Online: 12 February 2020
Compliance with Ethical Standards
:
: Shinya Matsuzaki has received research funding from MSD.Maximilian Klar has served on advisory boards for Tesaro and GlaxoSmithKline.Mikio Mikami declares that he has no conflict of interest.Muneaki Shimada declares that he has no conflict of interest.Brendan H. Grubbs declares that he has no conflict of interest.Keiichi Fujiwara has received research funding from Kaken, Shionogi, AstraZeneca, Pfizer, Eisai, MSD, Taiho Oncology, Zeria, Chugai, GlaxoSmithKline, Eli Lilly, ImmunoGen, OncoTherapy Science, Regeneron, and Genmab; and has received compensation from AstraZeneca, Pfizer, Eisai, MSD, Taiho Oncology, Zeria, Chugai, Nihon Kayaku, Novartis, Kyowa Hakko Kirin, Janssen, Daiichi Sankyo, Mochida, and Genmab for service as a consultant.Lynda D. Roman has received compensation from Tempus and Quantgene for service as a consultant.Koji Matsuo has received honoraria from Chugai; a textbook editorial expense from Springer; and reimbursement for investigator meeting attendance expenses from VBL Therapeutics.
: This article does not contain any studies with human or animal subjects performed by any of the authors.